Liao Shiyi, Zhou Mengjie, Wang Youjuan, Lu Chang, Yin Baoli, Zhang Ying, Liu Huiyi, Yin Xia, Song Guosheng
State Key Laboratory for Chemo, Biosensing and Chemometrics, College of Chemistry and Chemical, Engineering, Hunan University, Changsha 410082, China.
iScience. 2023 Jul 3;26(8):107277. doi: 10.1016/j.isci.2023.107277. eCollection 2023 Aug 18.
The tumor heterogeneity, which leads to individual variations in tumor microenvironments, causes poor prognoses and limits therapeutic response. Emerging technology such as companion diagnostics (CDx) detects biomarkers and monitors therapeutic responses, allowing identification of patients who would benefit most from treatment. However, currently, most US Food and Drug Administration-approved CDx tests are designed to detect biomarkers and , making it difficult to dynamically report variations of targets . Various medical imaging techniques offer dynamic measurement of tumor heterogeneity and treatment response, complementing CDx tests. Imaging-based companion diagnostics allow for patient stratification for targeted medicines and identification of patient populations benefiting from alternative therapeutic methods. This review summarizes recent developments in molecular imaging for predicting and assessing responses to cancer therapies, as well as the various biomarkers used in imaging-based CDx tests. We hope this review provides informative insights into imaging-based companion diagnostics and advances precision medicine.
肿瘤异质性导致肿瘤微环境的个体差异，进而导致预后不良并限制治疗反应。诸如伴随诊断（CDx）等新兴技术可检测生物标志物并监测治疗反应，从而能够识别出从治疗中获益最大的患者。然而，目前美国食品药品监督管理局批准的大多数CDx检测旨在检测生物标志物，这使得难以动态报告靶点的变化。各种医学成像技术可对肿瘤异质性和治疗反应进行动态测量，从而补充CDx检测。基于成像的伴随诊断可实现针对靶向药物的患者分层，并识别出可从替代治疗方法中获益的患者群体。本综述总结了分子成像在预测和评估癌症治疗反应方面的最新进展，以及基于成像的CDx检测中使用的各种生物标志物。我们希望本综述能为基于成像的伴随诊断提供有益的见解，并推动精准医学的发展。
